Rise in the Prevalence of Arthritis
The major risk factors associated with the onset of rheumatoid arthritis are - genetics, environmental factors, hormones, and sedentary lifestyles. According to the estimates of the Centre for Disease Control and Prevention, during 2013-2015, an estimated 54.4 million US adults (about 22.7%) annually, were diagnosed with some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.
Other factors, such as growing geriatric population and increasing acceptance of biopharmaceuticals are expected to drive the growth of the market studied, over the forecast period.
Alternative Treatment Options
The alternative treatment options, such as acupuncture, physical therapy, and occupational therapy are expected to hamper the market’s growth. Most of the patients prefer medications related to rheumatoid arthritis. However, medications are not quite effective against RA. Therefore, most of the patients suffering from RA are opting for the above-mentioned alternative therapies.
The other factor that acts as a restraint for the market studied is the patent expiration of blockbuster drugs of rheumatoid arthritis.
North America to Dominate the Market
North America dominates the global rheumatoid arthritis drugs market. The dominance of the region can be attributed to factors, such as ease of access to healthcare facilities, favorable reimbursement policies, robust clinical pipeline, and speedy approval of novel drugs. In addition, owing to increasing adoption of sedentary lifestyle, growing geriatric population, and immunological disorders, the region is experiencing a rise in the prevalence of rheumatoid arthritis. According to estimates of the Centre for Disease Control and Prevention (CDC) by 2040, about 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis. Hence, the aforementioned factors are expected to drive the growth of the North American segment of the market studied, over the forecast period.
Key Developments in the Market
- May 2018 - Sandoz, a Novartis division, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.
- December 2017 - AbbVie's Upadacitinib demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.
Reasons to Purchase this Report
- Current and future global rheumatoid arthritis drugs market outlook in the developed and emerging markets
- Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements. Please connect with our Customer Service Team, who will ensure that you to get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Pipeline Analysis
5.3 Porter's Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Consumers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitute Products and Services
5.3.5 Competitive Rivalry within the Industry
5.4 Regulatory Scenario
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Launch of Novel Biologics
6.1.2 Rise in the Prevalence of Arthritis
6.1.3 Increase in the Acceptance of Biopharmaceuticals
6.2 Market Restraints
6.2.1 Patent Expiration of Blockbuster Drugs
6.2.2 Alternative Treatment Options
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Molecule
7.2 By Drug Class
7.2.1 Non-steroidal Anti-inflammatory Drug (NSAID)
7.3 By Sales Channel
7.3.2 Over-the-counter (OTC)
7.4 By Geography
7.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 Australia and New Zealand
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.4.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
7.4.5 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 Bayer AG
9.4 Boehringer Ingelheim GmbH
9.5 Bristol-Myers Squibb Company
9.6 Celgene Corporation
9.7 F. Hoffmann-La Roche AG
9.8 Johnson & Johnson Services Inc.
9.9 Merck & Co. Inc.
9.10 Novartis AG
* List Not Exhaustive
10. Future of the Market